APLS vs. EIDX, RARX, OMER, MCRB, RIGL, BGNE, RDY, CTLT, QGEN, and PCVX
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Eidos Therapeutics (EIDX), Ra Pharmaceuticals (RARX), Omeros (OMER), Seres Therapeutics (MCRB), Rigel Pharmaceuticals (RIGL), BeiGene (BGNE), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Qiagen (QGEN), and Vaxcyte (PCVX). These companies are all part of the "medical" sector.
Eidos Therapeutics (NASDAQ:EIDX) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.
In the previous week, Apellis Pharmaceuticals had 17 more articles in the media than Eidos Therapeutics. MarketBeat recorded 17 mentions for Apellis Pharmaceuticals and 0 mentions for Eidos Therapeutics. Eidos Therapeutics' average media sentiment score of 0.48 beat Apellis Pharmaceuticals' score of 0.00 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.
Eidos Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
Apellis Pharmaceuticals received 175 more outperform votes than Eidos Therapeutics when rated by MarketBeat users. Likewise, 67.44% of users gave Apellis Pharmaceuticals an outperform vote while only 63.20% of users gave Eidos Therapeutics an outperform vote.
Eidos Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
31.4% of Eidos Therapeutics shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 70.1% of Eidos Therapeutics shares are held by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Apellis Pharmaceuticals has a consensus price target of $74.75, suggesting a potential upside of 88.05%. Given Eidos Therapeutics' higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Eidos Therapeutics.
Eidos Therapeutics has a net margin of 0.00% compared to Eidos Therapeutics' net margin of -79.67%. Apellis Pharmaceuticals' return on equity of -65.21% beat Eidos Therapeutics' return on equity.
Summary
Apellis Pharmaceuticals beats Eidos Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
Free APLS Stock Alerts